Molina Healthcare, Inc. (MOH) · Oct 21, 2026 · Earnings
Beat — Adjusted EPS $0.89 vs ~$0.79 consensus
Molina Healthcare’s Q3 earnings narrowly beat consensus and full-year guidance held, but higher medical costs and shrinking membership keep margins strained.
Molina is navigating a deliberately smaller, more focused business: Medicaid remains the core engine, while it is exiting traditional MAPD for 2027 and repositioning Medicare around dual-eligible members. The company is also absorbing the Florida CMS Medicaid rollout, which began October 1, 2026, and has already framed 2026 as a margin trough before expected benefit from newer rate updates.
The quarter cleared the earnings bar, but only narrowly. Adjusted EPS was $0.89 versus a published consensus near $0.79, making this a beat; however, adjusted EPS fell 53% year over year from $1.84, while premium revenue declined 4% to $10.5 billion.
| Metric | Q3 2026 | Q3 2025 | Change / expectation |
|---|---|---|---|
| Adjusted EPS | $0.89 | $1.84 | ~$0.79 consensus |
| GAAP EPS | $0.73 | $1.51 | Down 52% |
| Premium revenue | $10.457B | $10.841B | Down 4% |
| Consolidated MCR | 92.9% | 92.6% | Up 0.3 pts |
| Medicaid MCR | 93.0% | 92.0% | Up 1.0 pt |
| Total membership | 4.862M | 5.628M | Down 14% |
| 2026 adjusted EPS guidance | At least $5.25 | — | Reaffirmed |
The underlying operating picture is still strained. The consolidated medical care ratio worsened to 92.9%, with Medicaid—the largest segment—rising to 93.0% from 92.0%; that means more premium dollars are being consumed by medical costs before administration and other expenses. The company itself attributed the earnings decline mainly to the higher consolidated MCR. 〔0〕
Guidance held, but there was no new upside. Molina reaffirmed at least $5.25 of adjusted 2026 EPS and retained the previously disclosed $1.50-per-share Florida implementation hit and $1.00-per-share MAPD loss. This is better than a cut, but the main recovery thesis—medical-cost stabilization and stronger 2027 rates—remains prospective rather than demonstrated in this quarter.
Cash generation improved, though the quality of the improvement is partly working-capital driven. Nine-month operating cash flow was $629 million versus a $237 million outflow a year earlier, mainly because of lower government receivable and payable settlements, not because reported earnings improved.
Bottom line: This was a narrow earnings beat and a clean guidance reaffirmation, but it does not yet prove that Medicaid profitability has turned. The event modestly advances the recovery story through stable guidance, while the higher MCR and shrinking membership keep the business in transition.
October 22 earnings call on Medicaid margins and 2027 rates
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!